Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT05802121Phase 1Recruiting
Phase 1, randomised, open-label trial (2 arms), sponsored by Western University. Primary endpoints: Fecal Akkermansia muciniphilia counts at 6 months and Side effects and tolerability at 3 months. Started Jul 2025; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT05802121.